Drug Profile

AP 2 - Molefy Pharma

Alternative Names: AP-2 - Molefy Pharma

Latest Information Update: 22 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Molefy Pharma
Class Small molecules
Mechanism of Action TDP-43 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Amyotrophic lateral sclerosis
New Molecular Entity Yes

Highest Development Phases

Preclinical Amyotrophic lateral sclerosis

Most Recent Events

04 Dec 2025 Molefy Pharma receives patent for AP 2 for the treatment of Amyotrophic lateral sclerosis(Molefy Pharma pipeline, December 2025)
04 Dec 2025 Molefy Pharma plans a phase II trial for Amyotrophic lateral sclerosis in 2027(Molefy Pharma pipeline, December 2025)
04 Dec 2025 Molefy Pharma plans a phase I trial for Amyotrophic lateral sclerosis in beginning of 2026 (Molefy Pharma pipeline, December 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com